Business Description
WuXi Biologics (Cayman) Inc
ISIN : KYG970081090
Share Class Description:
WXIBF: Registered Shs Unitary 144A/Reg STotal Employee Number:
13,252Compare
Compare
Traded in other countries / regions
02269.Hong KongWXXWY.USAWUXI13.Thailand1FW2.Germany2269N.Mexico IPO Date
2017-10-06Description
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.07 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.42 | |||||
Interest Coverage | 49.41 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 8.47 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.9 | |||||
3-Year EBITDA Growth Rate | 13.8 | |||||
3-Year EPS without NRI Growth Rate | 5.2 | |||||
3-Year Book Growth Rate | 10.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.45 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.63 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 4.63 | |||||
9-Day RSI | 14.41 | |||||
14-Day RSI | 22.09 | |||||
3-1 Month Momentum % | -9.13 | |||||
6-1 Month Momentum % | -0.95 | |||||
12-1 Month Momentum % | 31.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.39 | |||||
Quick Ratio | 3.22 | |||||
Cash Ratio | 1.89 | |||||
Days Inventory | 46.64 | |||||
Days Sales Outstanding | 110.65 | |||||
Days Payable | 28.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 1.58 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.99 | |||||
Operating Margin % | 32.4 | |||||
Net Margin % | 22.52 | |||||
EBITDA Margin % | 33.96 | |||||
FCF Margin % | 12.07 | |||||
OCF Margin % | 29.2 | |||||
ROE % | 11.09 | |||||
ROA % | 8.2 | |||||
ROIC % | 12.8 | |||||
3-Year ROIIC % | 21.8 | |||||
ROC (Joel Greenblatt) % | 21.15 | |||||
ROCE % | 14.39 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 25.91 | |||||
Forward PE Ratio | 19.61 | |||||
PE Ratio without NRI | 22.58 | |||||
Shiller PE Ratio | 53.29 | |||||
Price-to-Owner-Earnings | 167.72 | |||||
PEG Ratio | 1.01 | |||||
PS Ratio | 5.76 | |||||
PB Ratio | 2.62 | |||||
Price-to-Tangible-Book | 2.74 | |||||
Price-to-Free-Cash-Flow | 47.75 | |||||
Price-to-Operating-Cash-Flow | 19.74 | |||||
EV-to-EBIT | 15.68 | |||||
EV-to-Forward-EBIT | 13.84 | |||||
EV-to-EBITDA | 15.68 | |||||
EV-to-Forward-EBITDA | 11.36 | |||||
EV-to-Revenue | 5.32 | |||||
EV-to-Forward-Revenue | 4.47 | |||||
EV-to-FCF | 44.31 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 4.94 | |||||
Price-to-DCF (Earnings Based) | 0.68 | |||||
Price-to-DCF (FCF Based) | 3.88 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.01 | |||||
Price-to-Graham-Number | 1.65 | |||||
| Price-to-Net-Current-Asset-Value | 10.53 | |||||
Earnings Yield (Greenblatt) % | 6.38 | |||||
FCF Yield % | 2.12 | |||||
Forward Rate of Return (Yacktman) % | 19.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:WXIBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
WuXi Biologics (Cayman) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,066.765 | ||
| EPS (TTM) ($) | 0.164 | ||
| Beta | -1.2399 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.19 | ||
| Volatility % | 44.75 | ||
| 14-Day RSI | 22.09 | ||
| 14-Day ATR ($) | 0.028756 | ||
| 20-Day SMA ($) | 4.238 | ||
| 12-1 Month Momentum % | 31.45 | ||
| 52-Week Range ($) | 3.18 - 5.606 | ||
| Shares Outstanding (Mil) | 4,108.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WuXi Biologics (Cayman) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
WuXi Biologics (Cayman) Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-20 20:00 | In 52 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 50 days | ||
| General meeting for 2025 | 2026-06-10 10:00 | 4.40 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 4.70 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 20:00 | 4.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 4.60 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-20 20:00 | 3.85 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 3.85 (+0.00%) | ||
| General meeting for 2024 | 2025-06-06 10:00 | 3.20 (+0.00%) | ||
| Annual report for 2024 | 2025-04-29 | 2.74 (+0.00%) |
Show
Entries
WuXi Biologics (Cayman) Inc Frequently Asked Questions
What is WuXi Biologics (Cayman) Inc(WXIBF)'s stock price today?
The current price of WXIBF is $4.00. The 52 week high of WXIBF is $5.61 and 52 week low is $3.18.
When is next earnings date of WuXi Biologics (Cayman) Inc(WXIBF)?
The next earnings date of WuXi Biologics (Cayman) Inc(WXIBF) is 2026-08-20 Est..
Does WuXi Biologics (Cayman) Inc(WXIBF) pay dividends? If so, how much?
WuXi Biologics (Cayman) Inc(WXIBF) does not pay dividend.
Guru Commentaries on OTCPK:WXIBF
No articles.
Press Release
Articles on WuXi Biologics (Cayman) Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers